Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Tumour-specific amplitude-modulated radiofrequency electromagnetic fields induce differentiation of hepatocellular carcinoma via targeting Cav3.2 T-type voltage-gated calcium channels and Ca2+ influx.

Jimenez H, Wang M, Zimmerman JW, Pennison MJ, Sharma S, Surratt T, Xu ZX, Brezovich I, Absher D, Myers RM, DeYoung B, Caudell DL, Chen D, Lo HW, Lin HK, Godwin DW, Olivier M, Ghanekar A, Chen K, Miller LD, Gong Y, Capstick M, D'Agostino RB Jr, Munden R, Merle P, Barbault A, Blackstock AW, Bonkovsky HL, Yang GY, Jin G, Liu L, Zhang W, Watabe K, Blackman CF, Pasche BC.

EBioMedicine. 2019 Jun;44:209-224. doi: 10.1016/j.ebiom.2019.05.034. Epub 2019 May 31.

2.

Lynch Syndrome Testing: A Missed Opportunity in the Era of Precision Medicine.

Pasche B, Pennison MJ, DeYoung B.

JAMA. 2016 Jul 5;316(1):38-9. doi: 10.1001/jama.2016.8291. No abstract available.

PMID:
27380341
3.

TGFBR1 and cancer susceptibility.

Pasche B, Pennison MJ, Jimenez H, Wang M.

Trans Am Clin Climatol Assoc. 2014;125:300-12. Review.

4.

Targeted treatment of cancer with radiofrequency electromagnetic fields amplitude-modulated at tumor-specific frequencies.

Zimmerman JW, Jimenez H, Pennison MJ, Brezovich I, Morgan D, Mudry A, Costa FP, Barbault A, Pasche B.

Chin J Cancer. 2013 Nov;32(11):573-81. doi: 10.5732/cjc.013.10177. Review.

5.

Characterization of the colorectal cancer-associated enhancer MYC-335 at 8q24: the role of rs67491583.

Tuupanen S, Yan J, Turunen M, Gylfe AE, Kaasinen E, Li L, Eng C, Culver DA, Kalady MF, Pennison MJ, Pasche B, Manne U, de la Chapelle A, Hampel H, Henderson BE, Marchand LL, Hautaniemi S, Askhtorab H, Smoot D, Sandler RS, Keku T, Kupfer SS, Ellis NA, Haiman CA, Taipale J, Aaltonen LA.

Cancer Genet. 2012 Jan-Feb;205(1-2):25-33. doi: 10.1016/j.cancergen.2012.01.005.

6.

Cancer cell proliferation is inhibited by specific modulation frequencies.

Zimmerman JW, Pennison MJ, Brezovich I, Yi N, Yang CT, Ramaker R, Absher D, Myers RM, Kuster N, Costa FP, Barbault A, Pasche B.

Br J Cancer. 2012 Jan 17;106(2):307-13. doi: 10.1038/bjc.2011.523. Epub 2011 Dec 1.

7.

Constitutively decreased TGFBR1 allelic expression is a common finding in colorectal cancer and is associated with three TGFBR1 SNPs.

Pasche B, Wisinski KB, Sadim M, Kaklamani V, Pennison MJ, Zeng Q, Bellam N, Zimmerman J, Yi N, Zhang K, Baron J, Stram DO, Hayes MG.

J Exp Clin Cancer Res. 2010 May 25;29:57. doi: 10.1186/1756-9966-29-57.

8.

Germline allele-specific expression of TGFBR1 confers an increased risk of colorectal cancer.

Valle L, Serena-Acedo T, Liyanarachchi S, Hampel H, Comeras I, Li Z, Zeng Q, Zhang HT, Pennison MJ, Sadim M, Pasche B, Tanner SM, de la Chapelle A.

Science. 2008 Sep 5;321(5894):1361-5. doi: 10.1126/science.1159397. Epub 2008 Aug 14.

Supplemental Content

Loading ...
Support Center